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liver transplantation is being used to treat (correct?) end-stage 
liYE'f disease caused by a wide variety of congenital or <lcquired 
dlsorders. Improved methods for procurement and presen-(ltion 
of donor livers, innovative surgical techniques, and reasonably 
satisfactory immunosuppression have made liver transplants fea-
sible for many with severely damaged liver parenchyma, vasculature, 
or bile ducts. One of the major difficulties has been the excessive 
use of blood transfusion, which reflects the loss of blood during 
the operation-_ This chapter deals with some of the many parameters' 
of coagulation and the changes found during the surgical procedure. 
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MATERIALS AND METHODS 
Patient Material 
In an 18-month period (12/03/82 to 5/28/84), intraoperative 
coagulation studies were carried out on 67 adult individuals under-
going their first liver transplants. The coagulation tests were 
performed at the request of the anesthesiologists or surgeons for 
patient care purposes and were not considered research, although 
the Coagulation Laboratory did allow a special, reduced price for 
each series of tests. The tests performed employed previously 
published methods (1-3) and included prothrombin time (PT), 
activated partial thromboplastin time (APTT), fibrin split products 
(FSP), euglobulin lysis time (EL T), and assays of coagulation factors 
I, II, V, VII, VIII, IX, X, XI, and XII. Frequently, but not always, 
platelet counts, thrombin times, and assays of plasminogen, anti-
plasmin (4), and F VIIIR:Ag were done. 
The 67 first liver transplants investigated represented all of 
the adult liver transplant procedures done during this period, with 
the exception of a few that were performed when our on-call 
technician was unavailable. 
Each study consisted of 12 or more samples that did not 
always follow a consistent time pattern. Usually, there was an 
initial sample, one taken just as the liver was isolated from the 
circulation, and another 5 min after circulatio'n was established in 
the new liver. Stage I (explantation of the diseased liver) begins 
with the skin incision, stage II (anhepatic) with removal of the 
patient's liver from the circulation, and stage III (implantation of 
the new liver) with restoration of circulation to the implant. 
Patient Categorization 
Table 12.1 shows the diagnostic categories. P;-":C includes 
chronic active hepatitis (CAH) following hepatitis B or nonA, 
nonB and lupoid hepatitis. (Alcoholic cirrhotics are very rarely 
suitable for transplant therapy.) Most of the CA group suffered 
from hepatoma, but one each had cholangiocarcinoma and angio-
carcinoma. The MISC group included two with a-I-antitrypsin 
deficiency and three with Wilson's disease. The FUL group included 
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TABLE 12.1. Diagnostic Categories of 67 Patients Receiving Their 
First Liver Transplants (December 3, 1982 to May 28, 1984) 
Diagnosis No M F Agt Rnnge 
PNC-postnecrotic cirrhosis 18 11 7 19-53 
PBC-primary biliary cirrhosis 18 0 18 39-54 
SC-primary sclerosing cholangitis 9 6 3 23-46 
MISC-miscellaneous 9 5 4 16-41 
CA-neoplasia/malignancy 8 2 6 21-35 
FUL-fulminant hepatitis 5 5 0 25-57 
Total 67 29 38 19-54 
one due to gold toxicity, one following exposure to methylethylke-
tone and vinyl paint, and the remainder following viral infections. 
RESULTS 
Figures 12.1 through 12.4 illustrate the findings in a single 
patient (10378). She was a 35-year-old white woman with the 
diagnosis of angiosarcoma of the liver. Intraoperative blood use 
was high. During the 14-h procedure she received 148 units of red 
blood cells (RBCs), 128 units of fresh frozen plasma (FFP), 52 units 
. of platelets, and 30 bags of c~yoprecipitateK Figure 12.1 shows the 
levels of factors II, V, VII, and X during the operation. In this ~ 
patient, these factors were low initially owing to parenchymal 
liver disease. In the first hour she received 400 ml FFP, which 
resulted in a moderate increase in factor levels. During the anhe-
patic period the factors fell, but all except F V rose to preoperative 
levels by the end of surgery. 
Figure 12.2 shows a similar pattern occurring in factors I, IX, 
XI, and XII. All of these factors were in the normal range preopera-
tively. All fell during the anhepatic period and recovered by the 
end of surgery. There was no evidence to suggest activation of 
factor XII, which might be important to the fibrinolytic activation 
shown in Figure 12.3. 
Figure 12.3 shows the euglobulin lysis time (EL T) and the F 
VIII:C and F VIIIR:Ag. The EL T revealed rapid lysis (15 min) early 
in stage II that contin'ued throughout this period and into early 
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FIGURE 12.1. Intraoperative findings in coagulation factors II, V, VII 
and X. 
sta-ge III. Factor VIII:C fell from its high initiallevelof 1.45 U/ml to 
0.18 U/mlrat the end of the bypass, when circulation through the 
- new liver was established. There was a lag of about 1 h before 
VIII:C started to rise again. The extent of the fall in F VIII:C level 
and the fact that it was greater than that observed for some of the 
other clotting factors suggests that some active process was hap-
pening and that this did not simply reflect lack of production and 
irregular replacement therapy. 
In addition, factor VIIIR:Ag fell more slov,'ly and t(1 a Jesser 
extent than \·III:C. This discrepancy in the falls of F YIIl:e and 
VIlIR:Ag further enhances the argument for destruction of F 
VIII:C. The mechanism involved could be due to plasmin or to 
thrombin. In this patient, the latter explanation seems unlikely 
because there was no significant indication of disseminated intra-
vascular coagulation (DIC) such as fibrin monomer or increased 
split products. 
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FIGURE 12.2. Intraoperative findings in coagulation factors L IX, XI 
and XII. 
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FIGURE 12.3. Euglobulin lysis time (EL T), factor VIII:C and VIIIR:Ag 
during liver transplantation. 
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FIGURE 12.4. Euglobulin lysis time, plasminogen and anti-plasmin dur-
ing liver transplantation. 
Figure 12.4 shows the assay results for plasminogen and 
anti·plasmin. Plasminogen showed only a moderate drop during 
the anhepatic period. However, a-ntiplasmin fell sharply to an 
- undetectable level, then rose when the new liver circulation was 
established. There appeared to be a direct relationship between 
activation of the EL T and the subsequent abrupt fall in antiplasmin. 
In almost all of the 67 transplant patients, all coagulation 
factor levels fell during the anhepatic period and usually recovered 
toward the end of surgery. This pattern was seen with factors II, 
\,11, IX, X, Xl, Jnc1 \11. These changes ,HE' described elsewhere (,5) 
The rest of this charter deals with the fibrinulytic enZ\"lTIl' s\':'tem 
and factors V and VIII. 
Table 12.2 shows that the euglobulin lysis time became short 
E~ 105 min.) at some time, often on repeated observations, during 
Up~M of the operations. Very rapid lysis E~4R min.) was seen in 43 
(64%) of the 67 patients. Preoperatively, this test had shown 
abnormal fibrinolytic activity in 12 patients (17%). 
Table 12.3 shows that the initial F VIII:C levels were high 
(mean ='-1.97) and that they fell approximately 66% to 0.63 U/ml. 
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TABLE 12.2. Intraoperative Activation of the Fibrinolytic Enzyme 
System 
PreoperRtitlt, Retitle IntraoperatiTJe, Retitle 
No. % No. % 
PNC 7 38 16 88 
PBe 0 0 16 88 
SC 0 0 8 88 
MISC 3 33 8 88 
CA 0 0 4 50 
FUL 2 40 5 100 
All 12 17 57 85 
and trough levels of factor v:c. The initial levels were low (indica-
tive of severe liver parenchymal involvement). They fell to a mean 
level of 0.16 U/ml, which was remarkably consistent among dif-
ferent patient categories. Some 38 (56%) reached levels of 0.15 
U/ml or lower. Table 12.5 snows that blood use during surgery, 
which reflects blood loss, is very much greater if factor VII1:C falls 
to levels ~ 0.35 U/ml. The large users of blood are almost all 
deficient in factor VIII:C. 
COMMENT 
The fall and subsequent rise in factors II, VII, IX, X, XI, and XII 
seem to reflect poor or absent synthesis plus dilution due to 
TABLE 12.3. Initial and lowest (Trough) Levels of VIII:C 
h:i::",7,' F \ 'J.Tj: C TI'c .. .'·" F \"]]J:( Or."''-'-
rU/m::: S.D, lU,,,,!:! S.D.i (-',-! 
PNC 1.86 ± 0.84 0.56 ± 0.37 69 
PBC 2.25 ± 0.89 0.68 ± OAl 69 
SC 2.00 ± 1.03 0.60:t 0,45 68 
MiSe 1.92:t 0.72 0.58:t 0.50 69, 
CA 1.64:t 0.76 0.73:t 0.43 54 
FUL 1.97 ± 0.84 0.75 ± 0.54 61 
All 1.97·-;± 0.85 0.63 ± 0,49 66 
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TABLE 12.4. Initial and Lowest (Trough) Levels of V:C 
Initial F V:C Trough F V:C Decrel/se 
(Ulml ± S.D.) (Ulml ± S.D.) (%) 
PNC 0.29 ± 0.14 0.15 ± 0.07 48 
PBC 0.59 ± 0.22 0.16 ± 0.08 72 
SC 0.68 ± 0.50 0.16± 0.07 69 
MISC 0.39 ± 0.43 0.16 ± 0.10 39 
CA 0.71 ± 0.35 0.15± 0.06 75 
FUL 0.38± 0.18 0.17± o.oe; 46 
All 0.49± 0.31 0.16± 0.07 59 
This level is not in the hemorrhagic range, but there were 25 (37%) 
whose trough levels were~ 0.35 Ulml. Table 12.4 shows the initial 
hemorrhage and inadequate replacement with FFP and crystalloid 
solutions. On the other hand, the falls in factors VIII:C and Vare 
more abrupt and persistent, md for F VIII:C in particular seem to 
involve destruction during an active process such as fibrinolysis. 
Certainly, these two factors are known to be easily destroyed by 
fibrinolytic activity. 
It is theorized that during liver transplantation, a plasminogen 
activator appears in the circulation in sufficient strength to activate 
plasminogen (causing the rapid EL T) and that Circulating plasmin 
cleaves factors VIII and V; making the molecules- functionally 
deficient and, later, structurally abnormal (fall in F VIIIR:Ag shown 
in Figure 12.3). Activation of Protein C could also result in des-
truction of factors VIII and V. Future studies will explore this 
TABLE 12.5. Patients with Trough Blood Levels of V:C ~ 0.15 
Vlml and lor VIII:C ~ 0.35 Vlml and Blood Use 
"Bioo.t· USf No, usea 
Factor Number mean units 100 
V 18 44 1 
VIII 7 99 3 
V+VJII 18 106 6 
Neither 24 36 1 
"Blood" = units FFP + RBC. 
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possibility. DIC causes multifactor and platelet consumption and 
the appearance of fibrin split products (FSP). These were found, 
but in minimal amounts, during liver transplantation. The mecha-
nism of activation of fibrinolysis will require future exploration. 
The intraoperative blood use (or loss) is highly dependent on 
the presence or absence of an abrupt and startling decline in factor 
VIII:C. When this occurs, the blood use is more than double that 
which occurs when it does not. Fortunately, plasma fractions high 
in factor VIII (cryoprecipitate) are available for therapy. However, 
this may not be effective unless any active fibrinolytic process is 
stopped by the judicious use of enzyme inhibitors such as epsilon 
amino caproic acid. 
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